SEARCH

SEARCH BY CITATION

References

  • 1
    Hayat MJ,Howlader N,Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2007; 12: 2037.
  • 2
    Groopman JE,Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91: 16161634.
  • 3
    Penninx BW,Cohen HJ,Woodman RC. Anemia and cancer in older persons. [seecomment]. J Support Oncol 2007; 5: 107113.
  • 4
    Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000; 37(4 Suppl 6: ): 1417.
  • 5
    Canon JL,Vansteenkiste J,Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006; 98: 273284.
  • 6
    Chang J,Couture F,Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005; 23: 25972605.
  • 7
    Gabrilove JL,Cleeland CS,Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 28752882.
  • 8
    Hedenus M,Adriansson M,San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394403.
  • 9
    Littlewood TJ,Bajetta E,Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 28652874.
  • 10
    Vansteenkiste J,Pirker R,Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 12111220.
  • 11
    Bohlius J,Wilson J,Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006; 3: CD003407.
  • 12
    Ross SD,Allen IE,Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clin Ther 2006; 28: 801831.
  • 13
    Seidenfeld J,Piper M,Bohlius J, et al. Comparative effectiveness of epoetin and darbeopetin for managing anemia in patients undergoing cancer treatment. Agency for Healthcare Research and Quality, Executive Summary, No. 3, May 2006. Rockville, MD: Agency for Healthcare Research and Quality; 2006. [AHRQ 06-EHC008-1.]
  • 14
    Hershman DL,Buono DL,Malin J, et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009; 101: 16331641.
  • 15
    Larholt K,Burton T,Pashos CL, et al. Hemoglobin (Hb) levels prior to blood transfusions in oncology patients receiving chemotherapy and erythropoiesis-stimulating agents (ESAs): Observational data from the dosing and outcomes study of erythropoiesis-stimulating therapies (D.O.S.E.) registry. Presented at the Community Oncology Conference Washington, DC, February 1–3, 2008.
  • 16
    Larholt K,Burton T,Hoaglin DC, et al. Clinical and patient-reported outcomes based on achieved hemoglobin levels in chemotherapy-treated cancer patients receiving erythropoiesis-stimulating agents. Community Oncol 2009; 6: 403408.
  • 17
    Gilmore J,Feinberg BA,Gondesen T, et al. Hematologic and transfusion outcomes following implementation of the erythropoiesis-stimulating agent (ESA) National Coverage Determination (NCD) in Medicare cancer patients receiving chemotherapy. J Clin Oncol 2008; 26(Suppl):abstract 6548.
  • 18
    Cable R,Carlson B,Chamers L, et al. Practice Guidelines for Blood Transfusion: A CompilationFromRecent Peer-Reviewed Literature, 2nd ed. Available at: www.redcross.org.Accessed September 2008.
  • 19
    Goodnough LT,Brecher ME,Kanter MH, et al. Transfusion medicine. First of two parts—Blood transfusion. N Engl J Med 1999; 340: 438447.
  • 20
    Bokemeyer C,Aapro MS,Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40: 22012216.
  • 21
    Rizzo JD,Lichtin AE,Woolf SH, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 40834107.
  • 22
    Rodgers GM. Guidelines for supportive care: Cancer and treatment-related anemia: National Comprehensive Cancer Network. ed. v. 2.2004.
  • 23
    Amgen Inc. Amgen announces interim results of Aranesp® “PREPARE” study in breast cancer patients, Vol. 2007. Available at: http://www.amgen.com/media/media_pr_detail.jsp?year=2007&releaseID=1083091. Accessed 8 August 2010.
  • 24
    Leyland-Jones B,Semiglazov V,Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. [seecomment]. J Clin Oncol 2005; 23: 59605972.
  • 25
    Thomas G,Ali S,Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008; 108325.317–325.
  • 26
    Henke M,Laszig R,Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 12551260.
  • 27
    Overgaard J,Hoff C,Sand Hansen H, et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC)—the Danish Head and Neck Cancer Group (DAHANCA 10). Eur J Cancer 2007; 5: 7. [Abstract.]
  • 28
    Smith RE Jr, Aapro MS,Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008; 26: 10401050.
  • 29
    Wright JR,Ung YC,Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25: 10271032.
  • 30
    Department of Health and Human Services: Oncologic Drugs Advisory Committee; Notice of Meeting. Fed Reg 2008; 73: 11928.
  • 31
    Department of Health and Human Services: Oncologic Drugs Advisory Committee; Notice of Meeting. Fed Reg 2007; 72: 3285232853.
  • 32
    Department of Health and Human Services: Oncologic Drugs Advisory Committee; Notice of Meeting. Fed Reg 2004; 69: 1658216583.
  • 33
    Amgen Inc. Aranesp® (Darbepoetin alfa) Package Insert. Thousand Oaks, CA: Amgen Inc.; 2008.
  • 34
    Barrett-Lee PJ,Bailey NP,O'Brien ME, et al. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000; 82: 9397.
  • 35
    Couture F,Turner AR,Melosky B, et al. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. Oncologist 2005; 10: 6371.
  • 36
    Quirt I,Robeson C,Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001; 19: 41264134.
  • 37
    Schwartz RN. Anemia in patients with cancer: Incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm 2007; 64(3 Suppl 2): S5S13.
  • 38
    Henry DH,Viswanathan HN,Elkin EP, et al. Symptoms and treatment burden associated with cancer treatment: Results from a cross-sectional national survey in the U.S. Support Care Cancer 2008; 16: 791801.
  • 39
    Webert KE,Blajchman MA. Transfusion-related acute lung injury. Transfus Med Rev 2003; 17: 252262.
  • 40
    Kuehnert MJ,Roth VR,Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001; 41: 14931499.
  • 41
    Anderson KC,Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990; 323: 315321.
  • 42
    Greenberg PL. Myelodysplastic syndromes: Iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 2006; 4: 9196.
  • 43
    Alter HJ,Stramer SL,Dodd RY. Emerging infectious diseases that threaten the blood supply. Semin Hematol 2007; 44: 3241.
  • 44
    Amato A,Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006; 1:CD005033.
  • 45
    Whitaker BI,Sullivan M. The 2005 nationwide blood collection and utilization survey report. Washington, DC: US Department of Health and Human Services. Available at: http://www.hhs.gov/bloodsafety/2005NBCUS.pdf. Accessed on 9 August 2010.
  • 46
    Koch CG,Li L,Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358: 12291239.
  • 47
    Projections of the Population by Selected Age Groups and Sex for the United States: 2010 to 2050 (NP2008-T2). Suitland, MD: U.S. Census Bureau; 2008.
  • 48
    Edwards BK,Howe HL,Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002; 94: 27662792.
  • 49
    Vekeman F,Bookhart BK,White J, et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion 2009; 49: 895902.